Skip to main content
Top
Published in: BMC Public Health 1/2014

Open Access 01-12-2014 | Research article

The lipid profile of HIV-infected patients receiving antiretroviral therapy in a rural Cameroonian population

Authors: Cavin Epie Bekolo, Modestine Becker Nguena, Leonard Ewane, Patrick Sylvestre Bekoule, Basile Kollo

Published in: BMC Public Health | Issue 1/2014

Login to get access

Abstract

Background

Long term use of antiretroviral therapy (ART) in persons living with human immunodeficiency virus (PLWHIV) is associated with disturbances in blood lipids which should be monitored. More data on such disturbances are needed in Cameroon to persuade the country program to institute their routine monitoring. We then sought to determine the prevalence and timing of dyslipidaemia in PLWHIV and receiving ART in a predominantly rural Cameroonian setting.

Methods

A cross-sectional study conducted between August and October 2012 in HIV-infected persons aged 15 years or more and receiving first-line ART for at least six months at The Nkongsamba Regional Hospital in Cameroon. Lipid assays were carried out by enzymatic-linked colorimetric methods. A multiple logistic regression model was used to assess for factors related to dyslipidaemia.

Results

Included were 114 participants of whom 83 (72.8%) were females. Their median age was 43 years (IQR: 36–51) and their median CD4 count was 436 cells/μl (IQR: 275–585) after a median duration on ART of 36 months (IQR: 12–60). The prevalence of dyslipidaemia was 70.2%. Hypercholesterolaemia was observed in 34 (29.8%) patients. One-third of them had a high LDL-cholesterol level (LDL-c ≥ 130 mg/dl). Hypertriglyceridaemia (TG ≥ 150 mg/dl) was present in 59 (51.8%) cases. The proportion of patients with a low HDL-cholesterol (HDL-c < 40 mg/dl) was 18.4% while those with a ratio of TC/HDL-c ≥ 5 were about 16.7%. A duration of 2–4 years on ART (adjusted Odd Ratio, aOR = 5.22, 95% CI: 1.43-19.06, p = 0.01), current smokers (aOR = 15.94, 95% CI: 1.13-225.61, p = 0.04) and a concurrent metabolic disease (aOR = 12.54, 95% CI: 1.02-153.86, p = 0.48) were independently associated with pro-atherogenic LDL-c values. Alcohol users had a more friendly LDL-c profile (aOR = 0.24, 95% CI: 0.07-0.74, p = 0.01).

Conclusion

The study has demonstrated a high prevalence of dyslipidaemia in HIV-patients receiving first-line ART in a predominantly rural setting of Cameroon. There is a need for the country HIV program to institute laboratory monitoring of blood lipids in patients over two years on first line ART with a focus on smokers.
Appendix
Available only for authorised users
Literature
1.
go back to reference Joint United Nations Programme on HIV/AIDS (UNAIDS): Global Report: UNAIDS Report on the Global AIDS Epidemic 2013. 2013, Geneva: UNAIDS Joint United Nations Programme on HIV/AIDS (UNAIDS): Global Report: UNAIDS Report on the Global AIDS Epidemic 2013. 2013, Geneva: UNAIDS
2.
go back to reference Cohan GR: HIV-associated metabolic and morphologic abnormality syndrome:Welcome therapy may have unwelcome effects. Postgrad Med. 2000, 107: 141-146.CrossRefPubMed Cohan GR: HIV-associated metabolic and morphologic abnormality syndrome:Welcome therapy may have unwelcome effects. Postgrad Med. 2000, 107: 141-146.CrossRefPubMed
5.
go back to reference Friis-Moller N, Weber R, Reiss P: Cardiovascular disease risk factors in HIV patients–association with antiretroviral therapy, Results from the DAD study. AIDS. 2003, 17 (8): 1179-1193. 10.1097/00002030-200305230-00010.CrossRefPubMed Friis-Moller N, Weber R, Reiss P: Cardiovascular disease risk factors in HIV patients–association with antiretroviral therapy, Results from the DAD study. AIDS. 2003, 17 (8): 1179-1193. 10.1097/00002030-200305230-00010.CrossRefPubMed
6.
go back to reference Central Bureau of the Census and Population Studies: La population du Cameroun en 2010. 2010, Yaounde: Central Bureau of the Census and Population Studies Central Bureau of the Census and Population Studies: La population du Cameroun en 2010. 2010, Yaounde: Central Bureau of the Census and Population Studies
7.
go back to reference National Institute of Statistics: Enquête Démographique et de Santé et à Indicateurs Multiples EDS-MICS 2011. 2011, Yaounde: National Institute of Statistics National Institute of Statistics: Enquête Démographique et de Santé et à Indicateurs Multiples EDS-MICS 2011. 2011, Yaounde: National Institute of Statistics
8.
go back to reference Ministere de la Sante Publique du Cameroun: Rapport annuel des activités de lutte contre le VIH et les IST au Cameroun. 2011, Yaounde: Ministere de la Sante Publique du Cameroun Ministere de la Sante Publique du Cameroun: Rapport annuel des activités de lutte contre le VIH et les IST au Cameroun. 2011, Yaounde: Ministere de la Sante Publique du Cameroun
9.
go back to reference Ngondi JL, Oben J, Forkah DM, Etame LH, Mbanya D: The effect of different combination therapies on oxidative stress markers in HIV infected patients in Cameroon. AIDS Res Ther. 2006, 3: 19-10.1186/1742-6405-3-19.CrossRefPubMedPubMedCentral Ngondi JL, Oben J, Forkah DM, Etame LH, Mbanya D: The effect of different combination therapies on oxidative stress markers in HIV infected patients in Cameroon. AIDS Res Ther. 2006, 3: 19-10.1186/1742-6405-3-19.CrossRefPubMedPubMedCentral
10.
go back to reference Teto G, Kanmogne GD, Torimiro JN, Alemnji G, Nguemaim FN, Takou D, Nanfack A, Asonganyi T: Lipid peroxidation and total cholesterol in HAART-naïve patients infected with circulating recombinant forms of human immunodeficiency virus type-1 in Cameroon. PLoS ONE. 2013, 8 (6): e65126-10.1371/journal.pone.0065126.CrossRefPubMedPubMedCentral Teto G, Kanmogne GD, Torimiro JN, Alemnji G, Nguemaim FN, Takou D, Nanfack A, Asonganyi T: Lipid peroxidation and total cholesterol in HAART-naïve patients infected with circulating recombinant forms of human immunodeficiency virus type-1 in Cameroon. PLoS ONE. 2013, 8 (6): e65126-10.1371/journal.pone.0065126.CrossRefPubMedPubMedCentral
11.
go back to reference Ngogang J, Oumarou A, Mbuagbaw J, Mbanya D: Proceedings of the 6th Congress of Cameroon Cardiac Society. Lipides et lipoprotéines des sujets camerounais VIH positifs naifs aux antirétroviraux. 2008, PAMJ, 10- Ngogang J, Oumarou A, Mbuagbaw J, Mbanya D: Proceedings of the 6th Congress of Cameroon Cardiac Society. Lipides et lipoprotéines des sujets camerounais VIH positifs naifs aux antirétroviraux. 2008, PAMJ, 10-
12.
go back to reference Nguemaim NF, Mbuagbaw J, Nkoa T, Alemnji G, Teto G, Fanhi TC, Asonganyi T, Same-Ekobo A: Serum lipid profile in highly active antiretroviral therapy-naïve HIV-infected patients in Cameroon: a case–control study. HIV Med. 2010, 11 (6): 353-359.PubMed Nguemaim NF, Mbuagbaw J, Nkoa T, Alemnji G, Teto G, Fanhi TC, Asonganyi T, Same-Ekobo A: Serum lipid profile in highly active antiretroviral therapy-naïve HIV-infected patients in Cameroon: a case–control study. HIV Med. 2010, 11 (6): 353-359.PubMed
13.
go back to reference World Health Organisation: Antiretroviral Therapy for HIV Infection in Adults and Adolescents. Recommendations for a Public Health Approach. 2010, revision. http://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf World Health Organisation: Antiretroviral Therapy for HIV Infection in Adults and Adolescents. Recommendations for a Public Health Approach. 2010, revision. http://​whqlibdoc.​who.​int/​publications/​2010/​9789241599764_​eng.​pdf
14.
go back to reference Pefura Yone EW, Betyoumin AF, Kengne AP, Folefack FJK, Ngogang J: First-line antiretroviral therapy and dyslipidemia in people living with HIV-1 in Cameroon: a cross-sectional study. AIDS Res Ther. 2011, 8: 33-10.1186/1742-6405-8-33.CrossRefPubMedPubMedCentral Pefura Yone EW, Betyoumin AF, Kengne AP, Folefack FJK, Ngogang J: First-line antiretroviral therapy and dyslipidemia in people living with HIV-1 in Cameroon: a cross-sectional study. AIDS Res Ther. 2011, 8: 33-10.1186/1742-6405-8-33.CrossRefPubMedPubMedCentral
15.
go back to reference Lissock CNAA, Sobngwi E, Ngassam E, Ngoa LSE: Rural and urban differences in metabolic profiles in a Cameroonian population. PAMJ. 2011, 10: 1-PubMedPubMedCentral Lissock CNAA, Sobngwi E, Ngassam E, Ngoa LSE: Rural and urban differences in metabolic profiles in a Cameroonian population. PAMJ. 2011, 10: 1-PubMedPubMedCentral
16.
go back to reference Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem. 1972, 18 (6): 499-502.PubMed Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem. 1972, 18 (6): 499-502.PubMed
17.
go back to reference Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001, 285 (19): 2486-2497. 10.1001/jama.285.19.2486. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001, 285 (19): 2486-2497. 10.1001/jama.285.19.2486.
18.
go back to reference Tadewos A, Addis Z, Ambachew H, Banerjee S: Prevalence of dyslipidemia among HIV-infected patients using first-line highly active antiretroviral therapy in Southern Ethiopia: a cross-sectional comparative group study. AIDS Res Ther. 2012, 9 (1): 31-10.1186/1742-6405-9-31.CrossRefPubMedPubMedCentral Tadewos A, Addis Z, Ambachew H, Banerjee S: Prevalence of dyslipidemia among HIV-infected patients using first-line highly active antiretroviral therapy in Southern Ethiopia: a cross-sectional comparative group study. AIDS Res Ther. 2012, 9 (1): 31-10.1186/1742-6405-9-31.CrossRefPubMedPubMedCentral
19.
go back to reference Armstrong C, Liu E, Grinspoon S, Okuma J, Spiegelman D, Guerino C, Njelekela M, Fawzi W, Hawkins C: Dyslipidemia in an HIV-positive antiretroviral treatment-naive population in Dar es Salaam Tanzania. J Acquir Immune Defic Syndr. 2011, 57 (2): 141-145. 10.1097/QAI.0b013e318219a3d1.CrossRefPubMedPubMedCentral Armstrong C, Liu E, Grinspoon S, Okuma J, Spiegelman D, Guerino C, Njelekela M, Fawzi W, Hawkins C: Dyslipidemia in an HIV-positive antiretroviral treatment-naive population in Dar es Salaam Tanzania. J Acquir Immune Defic Syndr. 2011, 57 (2): 141-145. 10.1097/QAI.0b013e318219a3d1.CrossRefPubMedPubMedCentral
21.
go back to reference Pernerstorfer-Schoen H, Jilma B, Perschler A, Wichlas S, Schindler K, Schindl A, Rieger A, Wagner OF, Quehenberger P: Sex differences in HAART-associated dyslipidaemia. AID. 2001, 15 (6): 725-734. 10.1097/00002030-200104130-00008.CrossRef Pernerstorfer-Schoen H, Jilma B, Perschler A, Wichlas S, Schindler K, Schindl A, Rieger A, Wagner OF, Quehenberger P: Sex differences in HAART-associated dyslipidaemia. AID. 2001, 15 (6): 725-734. 10.1097/00002030-200104130-00008.CrossRef
22.
go back to reference Daniyam C, Iroezindu M: Lipid profile of anti-retroviral treatment-naive HIV-infected patients in Jos Nigeria. Ann Med Health Sci Res. 2013, 3 (1): 26-30. 10.4103/2141-9248.109468.CrossRefPubMedPubMedCentral Daniyam C, Iroezindu M: Lipid profile of anti-retroviral treatment-naive HIV-infected patients in Jos Nigeria. Ann Med Health Sci Res. 2013, 3 (1): 26-30. 10.4103/2141-9248.109468.CrossRefPubMedPubMedCentral
23.
go back to reference Oka F, Naito T, Oike M, Imai R, Saita M, Inui A, Mitsuhashi K, Isonuma H, Shimbo T: Correlation between HIV disease and lipid metabolism in antiretroviral-naive HIV-infected patients in Japan. J Infect Chemother. 2012, 18 (1): 17-21. 10.1007/s10156-011-0275-5.CrossRefPubMed Oka F, Naito T, Oike M, Imai R, Saita M, Inui A, Mitsuhashi K, Isonuma H, Shimbo T: Correlation between HIV disease and lipid metabolism in antiretroviral-naive HIV-infected patients in Japan. J Infect Chemother. 2012, 18 (1): 17-21. 10.1007/s10156-011-0275-5.CrossRefPubMed
24.
go back to reference Kiage JN, Heimburger DC, Nyirenda CK, Wellons MF, Bagchi S, Chi BH, Koethe JR, Arnett DK, Kabagambe EK: Cardiometabolic risk factors among HIV patients on antiretroviral therapy. Lipids Health Dis. 2013, 12: 50-10.1186/1476-511X-12-50.CrossRefPubMedPubMedCentral Kiage JN, Heimburger DC, Nyirenda CK, Wellons MF, Bagchi S, Chi BH, Koethe JR, Arnett DK, Kabagambe EK: Cardiometabolic risk factors among HIV patients on antiretroviral therapy. Lipids Health Dis. 2013, 12: 50-10.1186/1476-511X-12-50.CrossRefPubMedPubMedCentral
25.
go back to reference Riddler SA, Smit E, Cole SR, Li R, Chmiel JS, Dobs A, Palella F, Visscher B, Evans R, Kingsle LA: Impact of HIV infection and HAART on serum lipids in men. JAMA. 2003, 289 (22): 2978-2982. 10.1001/jama.289.22.2978.CrossRefPubMed Riddler SA, Smit E, Cole SR, Li R, Chmiel JS, Dobs A, Palella F, Visscher B, Evans R, Kingsle LA: Impact of HIV infection and HAART on serum lipids in men. JAMA. 2003, 289 (22): 2978-2982. 10.1001/jama.289.22.2978.CrossRefPubMed
26.
go back to reference Ministere de la Sante Publique du Cameroun: Directives nationales de prise en charge par les antirétroviraux des personnes (Adultes et Adolescents) infectées par le VIH. 2010, Yaounde: Ministere de la Sante Publique du Cameroun Ministere de la Sante Publique du Cameroun: Directives nationales de prise en charge par les antirétroviraux des personnes (Adultes et Adolescents) infectées par le VIH. 2010, Yaounde: Ministere de la Sante Publique du Cameroun
27.
go back to reference Kumar PN, Rodriguez-French A, Thompson MA, Tashima KT, Averitt D, Wannamaker PG, Williams VC, Shaefer MS, Pakes GE, Pappa KA: A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity. HIV Med. 2006, 7 (2): 85-98. 10.1111/j.1468-1293.2006.00346.x.CrossRefPubMed Kumar PN, Rodriguez-French A, Thompson MA, Tashima KT, Averitt D, Wannamaker PG, Williams VC, Shaefer MS, Pakes GE, Pappa KA: A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity. HIV Med. 2006, 7 (2): 85-98. 10.1111/j.1468-1293.2006.00346.x.CrossRefPubMed
28.
go back to reference Eron JJ, Murphy RL, Peterson D: A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II). AIDS. 2000, 14: 1601-1610. 10.1097/00002030-200007280-00016.CrossRefPubMed Eron JJ, Murphy RL, Peterson D: A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II). AIDS. 2000, 14: 1601-1610. 10.1097/00002030-200007280-00016.CrossRefPubMed
29.
go back to reference Gallant JE, Staszewski S, Pozniak AL, De Jesus E, Suleiman JM, Miller MD, Coakley DF, Lu B, Toole JJ, Cheng AK: Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004, 292 (2): 191-201. 10.1001/jama.292.2.191.CrossRefPubMed Gallant JE, Staszewski S, Pozniak AL, De Jesus E, Suleiman JM, Miller MD, Coakley DF, Lu B, Toole JJ, Cheng AK: Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004, 292 (2): 191-201. 10.1001/jama.292.2.191.CrossRefPubMed
30.
go back to reference van Leth F, Phanuphak P, Stroes E, Gazzard B, Cahn P, Raffi F, Wood R, Bloch M, Katlama C, Kastelein JJ, Schechter M, Murphy RL, Horban A, Hall DB, Lange JM, Reiss P: Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med. 2004, 1 (1): e19-10.1371/journal.pmed.0010019.CrossRefPubMedPubMedCentral van Leth F, Phanuphak P, Stroes E, Gazzard B, Cahn P, Raffi F, Wood R, Bloch M, Katlama C, Kastelein JJ, Schechter M, Murphy RL, Horban A, Hall DB, Lange JM, Reiss P: Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med. 2004, 1 (1): e19-10.1371/journal.pmed.0010019.CrossRefPubMedPubMedCentral
31.
go back to reference Craig WY, Palomaki GE, Haddow JE: Cigarette smoking and serum lipid and lipoprotein concentrations: an analysis of published data. BMJ. 1989, 298 (6676): 784-788. 10.1136/bmj.298.6676.784.CrossRefPubMedPubMedCentral Craig WY, Palomaki GE, Haddow JE: Cigarette smoking and serum lipid and lipoprotein concentrations: an analysis of published data. BMJ. 1989, 298 (6676): 784-788. 10.1136/bmj.298.6676.784.CrossRefPubMedPubMedCentral
32.
go back to reference Triant VA, Lee H, Hadigan C, Grinspoon SK: Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007, 92 (7): 2506-2512. 10.1210/jc.2006-2190.CrossRefPubMedPubMedCentral Triant VA, Lee H, Hadigan C, Grinspoon SK: Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007, 92 (7): 2506-2512. 10.1210/jc.2006-2190.CrossRefPubMedPubMedCentral
33.
go back to reference Neuman MG, Schneider M, Nanau RM, Parry C: Alcohol consumption, progression of disease and other comorbidities, and responses to antiretroviral medication in people living with HIV. AIDS Res Treat. 2012, 2012: 751827-PubMedPubMedCentral Neuman MG, Schneider M, Nanau RM, Parry C: Alcohol consumption, progression of disease and other comorbidities, and responses to antiretroviral medication in people living with HIV. AIDS Res Treat. 2012, 2012: 751827-PubMedPubMedCentral
34.
go back to reference Waskiewicz A, Sygnowska E: Alcohol intake and cardiovascular risk factor profile in men participating in the WOBASZ study. Kardiol Pol. 2013, 71 (4): 359-365. 10.5603/KP.2013.0063.CrossRefPubMed Waskiewicz A, Sygnowska E: Alcohol intake and cardiovascular risk factor profile in men participating in the WOBASZ study. Kardiol Pol. 2013, 71 (4): 359-365. 10.5603/KP.2013.0063.CrossRefPubMed
Metadata
Title
The lipid profile of HIV-infected patients receiving antiretroviral therapy in a rural Cameroonian population
Authors
Cavin Epie Bekolo
Modestine Becker Nguena
Leonard Ewane
Patrick Sylvestre Bekoule
Basile Kollo
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2014
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/1471-2458-14-236

Other articles of this Issue 1/2014

BMC Public Health 1/2014 Go to the issue